In a press release made public, the World Health Organization issued a strong recommendation in favor of the administration of Paxlovid (nirmatrelvir/ritonavir) to patients with benign and moderate forms of COVVI-19 most at risk of hospitalization.
For the WHO “this drug of better therapeutic choice for patients at high risk to date”.
The oral antiviral medication of Pfizer (a combination of nirmatular and ritonavir tablets) is highly recommended for patients with the covid-19-to-19 without severity which have the highest risk of developing a serious form and of being hospitalized, for example, non-vaccinated, elderly or immunocompromised patients.
However, several factors mean that this medication likely to save lives represents a major challenge for low and intermediate income countries: its availability, the lack of transparency of prices in the context of the bilateral agreements concluded by the producer, and the need to carry out rapid and accurate tests before administering it, warns the WHO.
This recommendation is based on new data from two randomized controlled trials of 1,078 patients. The data show that the risk of hospitalization is reduced by 85 % thanks to this treatment. In a high -risk group (risk of hospitalizations greater than 10 %), this represents 84 fewer hospitalizations for 1000 patients.
Note that Pfizer has signed an agreement to allow the manufacture and sale of its experimental covid-19 treatment pill in 95 developing countries.
Tunisia is among these countries. Tunisian industrialists are allowed to make it
